GCP
BBIO icon

GSA Capital Partners’s BridgeBio Pharma BBIO Stock Holding History

GSA Capital Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Buy
5,649
+2,820
+100% +$198K 0.03% 1112
2026
Q1 		$210K Buy
+2,829
New +$205K 0.01% 1433
2025
Q4 		– Sell
-7,299
Closed -$379K – 1676
2025
Q3 		$379K Sell
7,299
-1,841
-20% -$89.8K 0.03% 1048
2025
Q2 		$395K Sell
9,140
-1,389
-13% -$50.5K 0.03% 1086
2025
Q1 		$364K Buy
+10,529
New +$355K 0.03% 1018
2024
Q3 		– Sell
-21,421
Closed -$543K – 1598
2024
Q2 		$543K Buy
+21,421
New +$586K 0.04% 910
2023
Q4 		– Sell
-86,071
Closed -$2.27M – 1505
2023
Q3 		$2.27M Buy
+86,071
New +$2.44M 0.19% 74
2023
Q2 		– Sell
-27,908
Closed -$463K – 1517
2023
Q1 		$463K Sell
27,908
-9,593
-26% -$112K 0.05% 766
2022
Q4 		$286K Sell
37,501
-6,190
-14% -$59.3K 0.04% 954
2022
Q3 		$434K Sell
43,691
-61,486
-58% -$639K 0.06% 682
2022
Q2 		$955K Buy
105,177
+70,164
+200% +$587K 0.14% 165
2022
Q1 		$355K Buy
35,013
+21,124
+152% +$217K 0.05% 774
2021
Q4 		$232K Sell
13,889
-82,107
-86% -$3.47M 0.03% 1118
2021
Q3 		$4.5M Buy
95,996
+84,749
+754% +$4.54M 0.46% 8
2021
Q2 		$686K Buy
+11,247
New +$642K 0.08% 430
2021
Q1 		– Sell
-10,385
Closed -$738K – 1101
2020
Q4 		$738K Sell
10,385
-69,505
-87% -$3.35M 0.12% 226
2020
Q3 		$3M Buy
+79,890
New +$2.51M 0.5% 9

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

GSA Capital Partners's BBIO Position: Q2 2026 in Review

GSA Capital Partners increased its BridgeBio Pharma (BBIO) stake by 100% in Q2 2026, buying an estimated $198K and bringing the position to 5,649 shares worth $421K. The position accounts for 0.03% of the portfolio, ranked #1112.

GSA Capital Partners first reported a position in BBIO in Q3 2020 and has held it in 17 quarters since. The position peaked at $4.5M in Q3 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • GSA Capital Partners held 5,649 shares of BridgeBio Pharma worth $421K as of Q2 2026.
  • GSA Capital Partners bought 2,820 BridgeBio Pharma shares in Q2 2026, an estimated $198K.
  • BridgeBio Pharma made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1112 holding.
  • GSA Capital Partners first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 17 quarters since.
  • GSA Capital Partners's BridgeBio Pharma position peaked at $4.5M in Q3 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.